BioCentury
ARTICLE | Clinical News

Incyte halts Jakafi substudy in mCRC

January 28, 2016 2:24 AM UTC

Incyte Corp. (NASDAQ:INCY) slipped $9 (12%) to $65.99 in early after-hours trading after it said late Wednesday that it will stop early a substudy within a Phase II trial evaluating myelofibrosis drug Jakafi ruxolitinib to treat relapsed or refractory metastatic colorectal cancer.

Incyte said a planned interim analysis of Jakafi in combination with Stivarga regorafenib vs. placebo plus Stivarga "did not show a sufficient level of efficacy to warrant continuation" in mCRC patients with C-reactive protein (CRP) >10 mg/L. The trial also included a substudy of patients with CRP ≤10 mg/L. The Phase II study's primary endpoint was overall survival (OS). ...